Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.

Amonkar, Mayur M; Chase, Monica; Myer, Nicole M; Wang, Tongtong; Turzhitsky, Vladimir; Spira, Alexander

Amonkar, Mayur M; Chase, Monica; Myer, Nicole M; Wang, Tongtong; Turzhitsky, Vladimir; Spira, Alexander.

Afiliação

Amonkar MM; Merck & Co., Inc., Rahway, NJ, United States of America. Electronic address: mayur.amonkar@merck.com.
Chase M; Merck & Co., Inc., Rahway, NJ, United States of America.
Myer NM; Merck & Co., Inc., Rahway, NJ, United States of America.
Wang T; Merck & Co., Inc., Rahway, NJ, United States of America.
Turzhitsky V; Merck & Co., Inc., Rahway, NJ, United States of America.
Spira A; Ontada/US Oncology Research/Virginia Cancer Specialists, Fairfax, VA, United States of America.

Cancer Treat Res Commun ; 36: 100712, 2023.

Article em En | MEDLINE | ID: mdl-37301728

Assuntos

Neoplasias do Colo; Neoplasias Colorretais; Humanos; Fator A de Crescimento do Endotélio Vascular; Neoplasias Colorretais/tratamento farmacológico; Neoplasias Colorretais/genética; Neoplasias Colorretais/patologia; Intervalo Livre de Progressão

Palavras-chave

Colorectal cancer; MSI-H; Overall survival; Progression-free survival; Real-world; dMMR

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasias do Colo Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google